ACRIN Adverse Event Reporting Manual Revisions Presented by: Cornelia Tsikos, BS, MS

of 12
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
ACRIN Adverse Event Reporting Manual Revisions Presented by: Cornelia Tsikos, BS, MS. Revisions to the Adverse Event Reporting Manual Introduction of the Regulatory Resources Webpage. Overview. Alphabetized list and addition of . . . Baseline Adverse Event C3D CAEPR
ACRIN Adverse Event Reporting Manual RevisionsPresented by: Cornelia Tsikos, BS, MSRevisions to the Adverse Event Reporting ManualIntroduction of the Regulatory Resources WebpageOverviewAlphabetized list and addition of . . .Baseline Adverse EventC3DCAEPR Comprehensive Adverse Events & Potential Risk ListExpedited ReportingRoutine ReportingSection 1: AE Terminology & DefinitionsSix Categories of ACRIN StudiesDiagnosticScreeningInterventional Investigational AgentsInvestigational DeviceCollaborativeSection 2: Adverse Event Reporting Reflects current practices Compliance with federal regulatory requirements  Protocol-specific AE reporting requirements will supersede the guidelines of the manual.Section 3: Expedited AE ReportingElectronic Adverse Event Reporting System(AdEERS) 24 hour electronic reporting instructionsSubmission through web applicationSystem unavailableTraining Assistance Section 3: Expedited AE Reporting Section 4: Reporting Requirements for Diagnostic StudiesSection 5: Reporting Requirements for Screening StudiesSection 6: Reporting Requirements for Interventional StudiesNew Sections in AE Reporting ManualSection 7: Reporting Requirements for Studies Using Investigational AgentsSection 8: Reporting Requirements for Studies Using Investigational DevicesSection 9: Reporting Requirements for Collaborative Clinical StudiesNew Sections in AE Reporting ManualACRIN’s Protocol Development & Regulatory ResourcesUpdated AE Reporting ManualAdEERS ResourcesNational Cancer Institute (NCI) ResourcesNCI Cancer Imaging Program (CIP)NCI Cancer Therapy Evaluation Program (CTEP)AdEERS ReportingU.S. Food and Drug Administration (FDA)Section 10: Additional ResourcesNCI-CIP AE Reporting Guidance Documents:Appendix 1: Phase 1 through Early Phase 2 CIP-IND Imaging Agent TrialsAppendix 2: Late Phase 2 through Phase 3 CIP-IND Imaging Agent TrialsAppendix 3: Commercial (Non-IND) Imaging Agent TrialsSection 11: AppendixAlways Available for QuestionsACRIN Adverse Event Coordinator(215)574-3150 Ask for an ACRIN AE CoordinatorAssistance Completing AdEERS ReportAdEERS MD Line (medical questions)(301)897-7497 adeersmd@tech-res.comAdEERS Technical Help(888)283-7457ncictephelp@ctep.nci.nih.govReminderCornelia (Lia) Tsikos, BS, MSACRIN AE Coordinator & ACRIN Research Associate ctsikos@acr-arrs.orgPhone: 215-574-3236Fax : 215-940-8819Contact Information
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!